GSK-backed startup has ambitious plans for immunology

There's quite a competition these days for the best minds in the field of adaptive immune responses, and GlaxoSmithKline has provided Tempero Pharmaceuticals with some of the hottest recruits to be found in this emerging class of new drugs. As Xconomy's Ryan McBride reports, GSK launched Tempero just a little more than a year ago to establish a leading position in this section of the immunology field, and it quickly focused on the top academics. "There was a realization that a lot of the basic...